Prostate Cancer Clinical Trial

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

Summary

This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.

View Full Description

Full Description

Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system. The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

The treatment is conducted completely within an MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland, thereby reducing the risk of possible damage to important surrounding anatomy such as the rectum, urinary sphincters, neurovascular bundles and pelvic bone. This coagulation method, therefore, has the potential to have lower complication rates than conventional therapies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male, age ≥65
Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0).
Gleason score 6 (3+3)
Prostate-specific antigen (PSA) ≤ 10 ng/ml
Eligible for MR imaging (DOC-10252)

Meets the following criteria on pre-treatment transrectal ultrasound imaging:

No cysts or calcifications > 1.0 cm in size
No evidence of extraprostatic extension or seminal vesicle invasion
Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter
Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment.
Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA)
Normal rectal anatomy and rectal mucosa on digital rectal examination

Exclusion Criteria:

Bleeding disorder
Abnormal coagulation and current anticoagulant therapy.
Acute or chronic Urinary Tract Infection
Interest in future fertility
History of allergy relevant medication or other
History of any other malignancy other than skin cancer
Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
Prior treatment of the prostate gland
Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months
History of any major rectal or pelvic surgery
History of ulcerative colitis or other chronic inflammatory conditions affecting rectum
History of documented clinical prostatitis requiring therapy within previous 6 months
History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter
Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic)
Neurologic bladder disorders
Untreated bladder stones
History of acute urinary retention
Confirmed or suspected bladder cancer
Urinary sphincter abnormalities
Active untreated gross hematuria for any cause
Post Void Residual (PVR) bladder volume > 250 mL
Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder

Additional exclusion criteria on file....

Study is for people with:

Prostate Cancer

Estimated Enrollment:

30

Study ID:

NCT01686958

Recruitment Status:

Completed

Sponsor:

Profound Medical Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

William Beaumont Hospital
Royal Oak Michigan, 48073, United States
London Health Science Centre
London Ontario, N6A 5, Canada
German Cancer Research Center (DKFZ)
Heidelberg , 69120, Germany

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

30

Study ID:

NCT01686958

Recruitment Status:

Completed

Sponsor:


Profound Medical Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider